研究疾病:
|
慢性前列腺炎
|
研究疾病代码:
|
|
Target disease:
|
Chronic prostatitis
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
其它
Others
|
研究目的:
|
慢性前列腺炎(CP)是成年男性常见的泌尿生殖系疾病,发病率高,病症复杂,病程缠绵,严重影响患者的生活质量。目前基层医疗机构受限制于基层医疗条件和医疗水平,缺乏治疗慢性前列腺炎的有效手段。我科在李曰庆教授和李海松教授的带领下,从流行病学研究、临床随机对照研究、理论探讨等方面围绕慢性前列腺炎取得了连续性的成果。前期我们通过北京市中医药管理局局级课题、“十一五”国家科技支撑计划、国家中医药管理局课题等多项课题的研究,证实了前列安栓联合脐疗外治CP的安全性和有效性,形成了中药外治慢性前列腺炎的规范治疗方案。以此为背景,本课题设计推广应用方案,以东直门医院男科为主要负责单位,联合三家社区卫生服务中心,开展CP外治法的基层医生培训讲座、患者健康咨询等活动,同时进行900例CP患者的临床推广观察及疗效评价,以期在临床推广这种有效、规范、易操作、患者易接受、疗效易评价的慢性前列腺炎中药外治方案。
|
Objectives of Study:
|
Chronic prostatitis (CP) is a common genitourinary disease in adult males. It has a high incidence, complicated illness and lingering disease, which seriously affects the quality of life of patients. At present, primary medical institutions are restricted to primary medical conditions and medical standards, and there is no effective means for treating chronic prostatitis. Under the leadership of Professor Li Zhaoqing and Professor Li Haisong, our department has made continuous progress around chronic prostatitis from epidemiological studies, clinical randomized controlled studies, and theoretical discussions. In the early stage, we confirmed the safety of Qianlie Anshuan combined with umbilical external treatment CP through the research of the Beijing Municipal Bureau of Traditional Chinese Medicine, the Eleventh Five-Year National Science and Technology Support Program, and the National Administration of Traditional Chinese Medicine. And the effectiveness, the formation of a standard treatment program for the treatment of chronic prostatitis. Based on this background, the project designed and promoted the application program, with the male department of Dongzhimen Hospital as the main responsible unit, and the three community health service centers, the grassroots doctor training lectures and patient health consultation activities of the CP external treatment method, and 900 cases of CP at the same time. The patient's clinical promotion observation and efficacy evaluation, in order to clinically promote this effective, standardized, easy to operate, easy to accept patients, easy to evaluate the efficacy of chronic prostatitis Chinese medicine treatment.
|
药物成份或治疗方案详述:
|
对照组:
前列安栓由丽珠医药贸易有限公司提供,2g/粒。每晚睡前一粒,纳肛,塞入肛门约3-4cm处;
试验组:
将丁香、肉桂按3:10的比例制成粉末,过120目筛,混匀装袋密封,每袋1g;(药物由东直门医院制剂室统一制备,外观相同,用首创大地公司生产的中药配方颗粒调配系统调配装袋入专用中药防潮袋),每次治疗时,取1袋药粉倒入药杯(江苏康健尿杯),用2ml注射器抽取1ml食用醋(“老才臣”牌米醋),注入药杯,将药粉调和成团,用40度温水清洗脐窝(神阙穴),用消毒棉球擦干,把药团涂于神阙穴,外盖一次性医用敷料(广州科美6×7cm敷料)固定, 每天换药1次。治疗疗程6周。
|
Description for medicine or protocol of treatment in detail:
|
Control group:
Qianlie Anshuan is provided by Lizhu Pharmaceutical Trading Co., Ltd., 2g/granule. One tablet per night before going to bed, anal anus, stuffed into the anus about 3-4cm;
Experimental group:
The cloves and cinnamon are made into a powder at a ratio of 3:10, passed through a 120 mesh sieve, and mixed and sealed in a bag, 1 g per bag; It is prepared by the preparation room of Dongzhimen Hospital. It has the same appearance. It is packaged into a special Chinese medicine moisture-proof bag by using the Chinese medicine formula granule mixing system produced by the first Dadi Company. For each treatment, take 1 bag of powder into the medicine cup (Jiangsu Kangjian Urine Cup)), use 1ml syringe to extract 1ml of edible vinegar ("Old Caichen" brand rice vinegar), inject the medicine cup, mix the powder into a group, wash the umbilical fossa with 40 degrees warm water, dry with a sterile cotton ball, The drug group was applied to the Shenque point, and the disposable medical dressing (Guangzhou Kemei 6×7cm dressing) was fixed, and the dressing was changed once a day. The treatment lasted for 6 weeks.
|
纳入标准:
|
(1)符合慢性非细菌性前列腺炎西医诊断标准者(2)符合气滞血瘀证辨证者(3)18岁≤年龄≤50岁(4)已签署知情同意书
|
Inclusion criteria
|
(1) Those who meet the Western diagnostic criteria for chronic non-bacterial prostatitis;
(2) Those who meet the syndrome of qi stagnation and blood stasis syndrome;
(3) Aged 18 to 50 years old;
(4) signed informed consent.
|
排除标准:
|
(1)合并严重神经管能症、尿道狭窄、前列腺肿瘤者(2)过敏体质及对多种药物过敏者(3)合并严重心血管疾病、脑血管疾病,肝肾功能不全、造血系统疾病,神经病患者(4)合并尿道炎、急性前列腺炎、泌尿系结石等疾病
|
Exclusion criteria:
|
(1) patients with severe neural tuberculosis, urethral stricture, prostate tumors;
(2) allergic constitution and allergy to various drugs;
(3) combined with severe cardiovascular disease, cerebrovascular disease, liver and kidney dysfunction, hematopoietic system disease, Neuropathy patients;
(4) with urethritis, acute prostatitis, urinary stones and other diseases.
|
研究实施时间:
Study execute time:
|
从From
2019-07-23
至To
2021-07-29
|
征募观察对象时间:
Recruiting time:
|
从From
2019-07-31
至To
2019-09-23
|